Document is current
Any future updates will be listed below
-
Authors
Miyawaki, Yutaka https://orcid.org/0000-0001-7141-2473
Tachimori, Hisateru
Nakajima, Yasuaki
Sato, Hiroshi
Fujiwara, Naoto
Kawada, Kenro
Miyata, Hiroaki
Sakuramoto, Shinichi
Shimada, Hideaki
Watanabe, Masayuki
Kakeji, Yoshihiro
Doki, Yuichiro
Kitagawa, Yuko
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
National Clinical Database
Johnson and Johnson
Nipro
Intuitive Surgical
Fujifilm Corporation
Asahi Kasei Pharma Corporation
Ono Pharmaceutical
Otsuka Pharmaceutical
Covidien
Taiho Pharmaceutical
Chugai Pharmaceutical
Kaken Pharmaceutical
Yakult Honsha
Tsumura and Company
Sumitomo Foundation
EA Pharma Co., Ltd.
Eisai
Kyowa Hakko Kirin
MEDICON INC
Teijin Pharma
Shionogi
Ethicon
Olympus
Bristol-Myers Squibb
AstraZeneca
MSD K.K.
Smith and Nephew
ASKA Pharmaceutical
Miyarisan Pharmaceutical
Toray Industries
Daiichi-Sankyo
Nippon Kayaku
- License Information
-
More Information
Article History
Received: 23 September 2022
Accepted: 3 March 2023
First Online: 10 March 2023
Declarations
:
: All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and later versions. The study protocol was approved by the Japanese Society of Gastroenterological Surgery and the Institutional Review Board of Edogawa Hospital (approval number 2020-19). The institutional review board waived the need for informed consent due to the retrospective nature of the study.
: Author H.T. belongs to an endowed course funded by Takeda Pharmaceutical Company Limited and belongs to a department that accepts financial support from National Clinical Database, Johnson & Johnson K.K., Nipro Corporation and Intuitive Surgical Sàrl. The author received a research grant from FUJIFILM Corporation. Author H.M. is affiliated with a social collaboration department supported by grants from National Clinical Database, Johnson & Johnson K.K., Nipro Co., and Intuitive Surgical Sàrl, Author Y.Ki. received grants or contracts from ASAHI KASEI PHARMA CORPORATION, ONO PHARMACEUTICAL CO., LTD., Otsuka Pharmaceutical Factory Inc., Nippon Covidien Inc., TAIHO PHARMACEUTICAL CO., LTD., CHUGAI PHARMACEUTICAL CO., LTD., KAKEN PHARMACEUTICAL CO., LTD., Yakult Honsha Co. Ltd., Otsuka Pharmaceutical Co., Ltd., TSUMURA & CO., Sumitomo Pharma Co., Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., MEDICON INC., Takeda Pharmaceutical Co., Ltd., and TEIJIN PHARMA LIMITED. Author Y.Ki also received lecture fees, etc. from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD., ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Factory Inc., SHIONOGI & CO., LTD., Nippon Covidien Inc., Ethicon, Inc., ONO PHARMACEUTICAL CO., LTD., Olympus Corporation, Bristol-Myers Squibb K.K., AstraZeneca K.K., MSD K.K., Smith & Nephew KK., KAKEN PHARMACEUTICAL CO.,LTD., ASKA Pharmaceutical Co., Ltd., MIYARISAN PHARMACEUTICAL CO. LTD., Toray Industries, Inc., DAIICHI SANKYO COMPANY, LIMITED, Chugai Foundation for Innovative Drug Discovery Science, Nippon Kayaku Co., Ltd., and EA Pharma Co., Ltd. Authors Y.M., Y.N., H.Sa., N.F., K.K., S.S., H.Sh., M.W., Y.Ka, and Y.D. declare that they have no conflict of interest.
